Out-of-pocket costs analysis of ifosfamide, epirubicin, and etoposide (IEV) and etoposide, solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) regimens in the patients with relapsed and refractory lymphoma in Iran
Journal Title: Chronic Diseases Journal - Year 2018, Vol 6, Issue 2
Abstract
BACKGROUND: This is an out-of-pocket costs analysis of ifosfamide, epirubicin, and etoposide (IEV) and etoposide, solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) drug regimens in treatment of lymphoma in Iran. METHODS: This cross-sectional study was conducted in Shiraz City. Data were collected using a data-collection form. The social perspective was used to collect cost data. Three types of costs were measured, medical direct costs, non-medical direct costs, and indirect costs. RESULTS: 65 patients were treated with these two methods; 27 patients were treated with IEV and 38 with ESHAP. Moreover, the mean direct cost in IEV and ESHAP regimens in 2014 were 1191.10 ± 610.74 and 1819.57 ± 789.73 United States dollars (USD), respectively. The difference was statistically significant (P < 0.001). CONCLUSION: In this study, costs in the IEV regimen were significantly lower than the ESHAP regimen. This was particularly caused by an earlier discharge of patients under IEV regimen; since these patients experienced a trend toward less neutropenia and, hence, had a trend toward fewer hospitalization days, the related cost was 3451.76 USD with savings of 6479.61 USD compared with the ESHAP regimen. Overall, most of patient’s income was spent on out-of-pocket costs for all expenditures incurred because of lymphoma.
Authors and Affiliations
Mostafa Habibian, Mehdi Dehghani
Keywords
Related Articles
- EP ID EP419566
- DOI 10.22122/cdj.v6i2.270
- Views 136
- Downloads 0
In vivo reprogramming: A new approach for tissue repair in chronic diseases
Medical researchers and biologists have long been fascinated by the possibility of changing the identity of cells, a phenomenon known as cellular plasticity. Now, we know that differentiated cells can be experimentally c...
Reducing the incidence of cancers in Iran with more attention to personal and environmental risk factors
-
Life expectancy in the families of patients with cancer: A qualitative study
BACKGROUND: The family of patient with cancer encounters stresses that are sometimes uncontrollable. One of the strategies to gain control is to deal with such a situation hopefully. Hope plays a key role in coping with...
Risk factors of chronic obstructive pulmonary disease in men and women in Sanandaj, Iran
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the world. While smoking has been identified as the main cause of COPD in many studies, other causes may include environmen...
The frequency of skin cancers in Kermanshah City, Iran, during the years 2003-2012
BACKGROUND: Skin cancer is the most common malignancy in the world, and besides the malignant type that has a high mortality rate, other cancers causes many complications and deaths as well. The incidence of skin cancer...